PlasmaGen Biosciences Raises INR 150 Crore from ViNS Bioproducts

PlasmaGen Biosciences raised INR 150 crore. The valuation came in over INR 1,500 crore. ViNS Bioproducts led the round. High-net-worth individuals, family offices, pharma entrepreneurs, and existing backers also put money in.
The company plans to use the funds for international growth, adding more products, and improving manufacturing and leadership. The CEO, Vivek V Kamath, said the last year brought big changes and set the company on a fast growth path.
Founder and executive chairman Vinod Nahar said the round shows trust in the goal to build a top plasma biopharma company based in India. PlasmaGen started in 2010. It recently started operations at a new plasma fractionation facility in Kolar near Bengaluru. The company has raised over INR 600 crore in total so far.
PlasmaGen Biosciences develops and manufactures therapies from blood plasma, like albumin and immunoglobulins. It supplies these to private hospitals and state governments across India. The company is based in Bengaluru.









